| 38.8427 4.703 (13.77%) | 11-11 15:52 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 49.46 |
1-year : | 57.77 |
| Resists | First : | 42.34 |
Second : | 49.46 |
| Pivot price | 36.84  |
|||
| Supports | First : | 36.37 |
Second : | 32.68 |
| MAs | MA(5) : | 35.28 |
MA(20) : | 37.64 |
| MA(100) : | 37.72 |
MA(250) : | 33.47 |
|
| MACD | MACD : | -1.6 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 33.1 |
D(3) : | 17.5 |
| RSI | RSI(14): 51.2 |
|||
| 52-week | High : | 54.18 | Low : | 20.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HROW ] has closed below upper band by 26.8%. Bollinger Bands are 10.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.92 - 36.12 | 36.12 - 36.31 |
| Low: | 32.92 - 33.17 | 33.17 - 33.4 |
| Close: | 33.77 - 34.14 | 34.14 - 34.48 |
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Tue, 11 Nov 2025
Earnings call transcript: Harrow Health Q3 2025 reports strong EPS beat - Investing.com India
Mon, 27 Oct 2025
Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 - Sahm
Tue, 07 Oct 2025
Could Harrow’s (HROW) New Pricing Program Redefine Its Patient Access Advantage? - Yahoo Finance
Mon, 06 Oct 2025
Frank Mullery named CEO; Bridseida Cruz named Head of Quality at ImprimisRx, Harrow subsidiary - Stock Titan
Mon, 06 Oct 2025
Harrow Health (HROW) Appoints New Leadership at ImprimisRx - GuruFocus
Mon, 06 Oct 2025
Harrow Health Announces New Leadership at ImprimisRx - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 37 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 15.7 (%) |
| Held by Institutions | 57.8 (%) |
| Shares Short | 5,700 (K) |
| Shares Short P.Month | 5,230 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.35 |
| Profit Margin | -4.5 % |
| Operating Margin | 17.8 % |
| Return on Assets (ttm) | 2.8 % |
| Return on Equity (ttm) | -19.1 % |
| Qtrly Rev. Growth | 30.2 % |
| Gross Profit (p.s.) | 4.58 |
| Sales Per Share | 6.15 |
| EBITDA (p.s.) | 0.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 4 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -137.41 |
| PEG Ratio | 0 |
| Price to Book value | 28.49 |
| Price to Sales | 6.25 |
| Price to Cash Flow | 352.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|